Close Menu

CytRx CEO Steven Kriegsman is scheduled to present at the Roth Capital Partners’ annual growth stock conference on Feb. 19, 2004, the company said this week.

Kriegsman is expected to highlight CytRx’s recent collaborations in the field of RNAi and small-molecule drug development, and also give an overview of the company’s other drug development programs.

The Roth meeting is scheduled for Feb. 16-19 at the St. Regis Monarch Beach Resort and Spa in Dana Point, Calif.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Springer Nature announces €9,500 fee to make papers open-access in Nature and its family of journals.

Librarians have concluded that notebooks that belonged to Charles Darwin that were thought to have been lost were actually likely stolen, CNN reports.

An early SARS-CoV-2 alteration may have enabled it to spread more easily, according to the New York Times.

In PNAS this week: ultrarare variants contribute to aging-related hearing loss, telomeres of cells infected with herpesvirus, and more.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion. 

Dec
10
Sponsored by
Tecan

CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology.